Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 23 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 23 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 20 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.